Remibrutinib 是有效的、口服具有活力的 bruton tyROSine kinase 抑制剂 (IC50:1 nM)，在血液中抑制 BTK 活性的IC50的值为 0.23 μM。它具有研究慢性荨麻疹的潜力。

Remibrutinib inhibits BTK activity with an IC50 value of 0.023 μM in blood. Remibrutinib is an effective and orally active Bruton tyrosine kinase inhibitor (IC50: 1 nM). Remibrutinib has the potential for Chronic urticaria (CU) treatment.

Remibrutinib inhibits Btk enzymatic activity (IC50: 1 nM in a biochemical enzyme assay). Remibrutinib inhibits Btk enzymatic activity in the blood (IC50: 0.023 μM in vitro B cell activation assay), the whole blood is collected from the abdominal aorta of anesthetized adult male Lewis rats[1].

1787294-07-8

C27H27F2N5O3

507.53

DMSO:125 mg/mL (246.29 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years